Sarepta Therapeutics, Inc. (SRPT) News

Sarepta Therapeutics, Inc. (SRPT): $70.52

0.49 (+0.70%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SRPT to Watchlist
Sign Up

Industry: Biotech


Ranked

of 493

in industry

Filter SRPT News Items

SRPT News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

SRPT News Highlights

  • SRPT's 30 day story count now stands at 23.
  • Over the past 26 days, the trend for SRPT's stories per day has been choppy and unclear. It has oscillated between 1 and 12.
  • The most mentioned tickers in articles about SRPT are GENE, MG and RBC.

Latest SRPT News From Around the Web

Below are the latest news stories about Sarepta Therapeutics Inc that investors may wish to consider to help them evaluate SRPT as an investment opportunity.

Here’s Why Artisan Partners Disposed its Sarepta Therapeutics Inc. (SRPT) Position

Artisan Partners, a high value-added investment management firm, published its ‘Artisan Mid Cap Fund’ first quarter 2021 investor letter – a copy of which can be downloaded here. A return of -2.36% was recorded by its Investor Class: ARTMX, -2.32% by its Advisor Class: APDMX, and -2.30% by its Institutional Class: APHMX, in the fourth quarter […]

Yahoo | May 7, 2021

Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram on Q1 2021 Results - Earnings Call Transcript

Sarepta Therapeutics, Inc. (SRPT) Q1 2021 Earnings Conference Call May 05, 2021, 5:30 PM ET Company Participants Mary Jenkins - IR Douglas Ingram - President, CEO & Director Ian Estepan - EVP & CFO Dallan Murray - SVP & Chief Commercial Officer Gilmore O'Neill - EVP, R&D and Chief Medical...

SA Transcripts on Seeking Alpha | May 6, 2021

Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -4.48% and 4.41%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | May 5, 2021

Sarepta Therapeutics Announces First Quarter 2021 Financial Results and Recent Corporate Developments

Net product sales for the first quarter 2021 of $124.9 million, a 24% increase over the same quarter of prior year CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the first quarter of 2021. “In the first quarter, we obtained FDA approval for and launched our third RNA therapy for Duchenne, AMONDYS 45™ (casimersen). The first AMONDYS 45 patient was treated within the first week of approval. Serving the community with EXONDYS 51, VYONDYS 53, and AMONDYS 45, we achieved net product revenue of $124.9 million, a 24% increase over the same quarter in 2020,” stated Doug Ingram, Sarepta’s president and CEO. “We also made significant strides in the advance...

Yahoo | May 5, 2021

Sarepta Therapeutics, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 5, 2021 / Sarepta Therapeutics, Inc. (NASDAQ:SRPT) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 5, 2021 at 4:30 PM Eastern Time.

Yahoo | May 5, 2021

Sarepta Therapeutics to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in fireside chats at two upcoming virtual investor conferences: BofA Securities Virtual 2021 Healthcare Conference on Tuesday, May 11 at 2:00 p.m. E.T.RBC 2021 Global Healthcare Conference on Tuesday, May 18 at 2:30 p.m. E.T. The presentations will be webcast live under the investor relations section of Sarepta’s website at www.sarepta.com and will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary. About Sarepta Ther...

Yahoo | May 4, 2021

Monthly Dosing Of Sarepta's Next-Gen Eteplirsen Can Potentially Achieve Over 10% Higher Dystrophin Expression In DMD Patients

Sarepta Therapeutics Inc (NASDAQ: SRPT ) announced positive results from Part A in a tiny group of 4 patients of the MOMENTUM Phase 2 study evaluating SRP-5051 in Duchenne muscular dystrophy (DMD) patients amenable to exon 51 skipping. SRP-5051 is the company's next-generation peptide phosphorodiamidate morpholino oligomer (PPMO). At a median of week 12, 30 mg/kg of SRP-5051 resulted in mean dystrophin production of 6.55% of normal. Dystrophin expression was measured … Full story available on Benzinga.com

Benzinga | May 3, 2021

Analysts Estimate Sarepta Therapeutics (SRPT) to Report a Decline in Earnings: What to Look Out for

Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | April 28, 2021

Sarepta Therapeutics to Announce First Quarter 2021 Financial Results and Recent Corporate Developments on May 5, 2021

CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2021 financial results after the Nasdaq Global Market closes on Wednesday, May 5, 2021. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its first quarter 2021 financial results and to provide a corporate update. The conference call may be accessed by dialing (844) 534-7313 for domestic callers and (574) 990-1451 for international callers. The passcode for the call is 6429649. Please specify to the operator that you would like to join the "Sarepta First Quarter 2021 Earnings Call." The conference call will be webcast live under the investor relations section of Sarepta.com a...

Yahoo | April 28, 2021

RBC Capital Stick to Their Buy Rating for Sarepta Therapeutics By Investing.com

RBC Capital Stick to Their Buy Rating for Sarepta Therapeutics

Investing.com | April 11, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.7002 seconds.